The 19th Annual San Diego BioPharma Conference

Agenda

9:00 am Welcome and Opening Remarks

Tao Wu, PhD, President, SABPA

Yi Liu, PhD, Chair, BioPharmaCommittee, SABPA; CEO, Kumqat Biosciences

9:15 am Floyd Romesberg, PhD Fellow, Sanofi

Presentation: “A semi-synthetic organism that stores and retrieves increased genetic information”

9:45 am Anthony Sun, PhD

Presentation: “So you want to start a biotech?The Zentalis Story from Napkin to IPO”

10:15 am Xuedong Dai,PhD Executive VP and Head of IDSU (International Discovery Service Unit), Medicilon

Sponsor Presentation: “PROTACs: Review and Support from Medicilon”

10:35 am Molly He, PhD CEO Element Biosciences

Presentation: “Play the Infinite Game –a personal journey to entrepreneurship in the genomics space”

11:05 am Peter Luo, PhD CEO & Chairman of the Board, Adagene

Presentation: “Raising the bar for differentiation in antibody-based technology and therapeutics”

11:35 am Annie Kadota, VP Southwest Life Science, Silicon Valley Bank

Presentation: “Healthcare Investments and Exits: Trends in 1H’2021”

12:05 pm Closing remarks by Hua Gong, MD, PhD, EVP, SABPA

Register for free at

https://us02web.zoom.us/webinar/register/WN_rp98qW-4RvC6T3wxS_jLTA

or scan QR code

The 19th Annual San Diego BioPharma Conference Speaker Biography

Floyd E. Romesberg received a B.S. and M.S in chemistry from The Ohio State University, and a Ph.D. in physical organic chemistry from Cornell University.From 1998 to 2019 he was a faculty member in the Chemistry Department at The Scripps Research Institute, where he led a research laboratory that applied organic chemistry, microbiology, non-linear optical spectroscopy, and genetics, to study different aspects of evolution. Of particular significance is his work to expand the genetic alphabet and code through the development of a third DNA base pair that relies on hydrophobicity as opposed to hydrogen bonding for selective pairing. Romesbergis the recipient of the Camille Dreyfus Teacher Scholar Award, the NSF CAREER Award, the Discover Magazine Technology Innovation Award, the ACS NobelLaureate Signature Award, and the Royal Society of Chemistry’s Bioorganic Chemistry Award. His research was funded by the National Institutes of Health, National Science Foundation, Office of Naval Research, and Defense Advanced Research Projects Agency. Romesberghas been elected to the National Academy of Inventors and is the scientific founder of the biotech companies Achaogen, Inc. and RQxInc., as well as Synthorx, Inc, which was acquired by Sanofi and where he is currently a Scientific Fellow working to use the expanded genetic alphabet to create novel therapeutics.

Anthony has played an active role across the life science industry since 2002 and currently serves as President and Chief Executive Officer for Zentalis Pharmaceuticals. From 2002 until 2015, he was at Aisling Capital and Perseus-Soros Biopharmaceutical Fund, private equity firm dedicated to the life sciences, during which he held multiple positions most recently as Partner. Dr.Sun holds a BS in Electrical Engineering from Cornell University, an MD from Temple University School of Medicine, an MBA from The Wharton School at the University of Pennsylvania. He trained in internal medicine at the Hospital of the University of Pennsylvania and was board certified in internalmedicine.

Molly co-founded Element Biosciences and has served as CEO since its inception. She has more than 20 years of experience in technology innovation and management in biotechnology and healthcare industries. Molly was previously a Venture Partner at ForesiteCapital, investing in some of the most exciting and innovative companies in healthcare. Before then, she was Senior Director at Illumina, responsible for Illumina’s global protein reagent innovation and improvements, and for leading global scientific and technical teams. She and her team have won twice the highest award for innovations with significant revenue impact at Illumina. Prior to Illumina, Molly was the Head of Protein Sciences at Pacific Biosciences, responsible for protein reagent development for their single-molecule real-time sequencing chemistry. She also has years of experience in the pharmaceutical industry. Molly holds a PhD from UCLA in protein biophysics.

Dr. Peter Luo is Co-Founder, CEO, and Chairman of the Board of Adagene. Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencorfrom 1998 to 2000. In 2000, Dr. Luo founded AbmaxisInc. and served as its Co-Founder, CTO, President, and Director until its acquisition by Merck, after which Dr. Luo served as a Director of Biologics Technology at Merck, and Chief Technology Officer of Abmaxis, the subsidiary of Merck. Dr. Luo received his bachelor’s degree in applied chemistry in technical physics from Peking University in 1986, master’s degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences in 1989, and Ph.D. degree in chemistry from The University of Chicago in 1995. Dr. Luo also completed his postdoctoral research in protein folding at Stanford University in 1998.

Annie Kadotais a VP in Silicon Valley Bank (SVB)’s Life Science and Healthcare Banking Solutions group, Southwest Region, where her specialty in venture debt supports the team’s deep expertise in providing financial solutions to high-growth public and private life science companies.Annie joined SVB in 2014 based in the Bay Area and returned to her hometown of San Diego in 2015 to join the Life Science Practice. Annie also serves as a committee chair for the Southern California chapter of Women in Bio, which promotes careers, leadership and entrepreneurship in the second-largest biotech hub in the United States. Annie graduated with a bachelor’s degree in sports management from Rice University, where she’d earned numerous academic and athletic awards as a four-year letter winner on the varsity soccer team. Outside of the office, Annie enjoys playing soccer, skiing in Whistler, and practicing piano/guitar.

Sponsor speaker Biography

Dr. Xuedong Dai, Executive VP and Head of IDSU (International Discovery Service Unit) at Medicilon, obtained his Ph.D. in organic chemistry at MIT. He is a senior-level expert with over 20 years of experience focusing on small molecule drug discovery and development in CNS, infectious disease, and oncology therapy areas. He has deep understanding and practical knowledge of drug discovery process, including lead identification, optimization, and development of high quality clinical candidate molecules. Prior to Medicilon, Dr. Dai worked at Janssen, HD Biosciences, GSK, and Xenoportwith a demonstrated successful track record of program leadership and made significant contributions to medicinal chemistry programs that led to the marketed drug Horizant®/Regnite® and several other clinical candidates (JNJ-75276617, arbaclofen placarbil, XP21279, and XP23829).

Medicilon’s PROTAC drug discovery technology platform covers the currently popular target protein ligands. Medicilon has established a linker system with an extensive collection of bifunctional linkers. Together with our expanding E3 ubiquitin ligase binder library, Medicilon can efficiently synthesize a substantial amount of highly active PROTAC bispecific small molecules, which would have the potential to significantly facilitate the drug discovery and development process. In addition, Medicilon has established as well as improved the PROTAC biological screening and testing platform throughout the pre-clinical stages.